Ad is loading...
GLNMX
Price
$23.59
Change
-$0.19 (-0.80%)
Updated
Nov 15 closing price
RSLDX
Price
$69.58
Change
-$0.86 (-1.22%)
Updated
Nov 15 closing price
Ad is loading...

GLNMX vs RSLDX

Header iconGLNMX vs RSLDX Comparison
Open Charts GLNMX vs RSLDXBanner chart's image
MFS Global New Discovery R4
Price$23.59
Change-$0.19 (-0.80%)
VolumeN/A
CapitalizationN/A
American Funds SMALLCAP World R5E
Price$69.58
Change-$0.86 (-1.22%)
VolumeN/A
CapitalizationN/A
GLNMX vs RSLDX Comparison Chart
Loading...
View a ticker or compare two or three
VS
GLNMX vs. RSLDX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GLNMX is a Buy and RSLDX is a Buy.

FUNDAMENTALS
Fundamentals
RSLDX has more cash in the bank: 74.7B vs. GLNMX (76M). RSLDX pays higher dividends than GLNMX: RSLDX (0.83) vs GLNMX (0.00). GLNMX was incepted earlier than RSLDX: GLNMX (13 years) vs RSLDX (9 years). GLNMX (29.00) and RSLDX (29.00) have comparable annual turnover. GLNMX has a lower initial minimum investment than RSLDX: GLNMX (0) vs RSLDX (250). RSLDX (16.23) and GLNMX (15.69) have marching annual gain over last year. RSLDX return over 5 years is better than : 20.19 vs. GLNMX (15.78).
GLNMXRSLDXGLNMX / RSLDX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence13 years9 years-
Gain YTD5.5483.928141%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets76M74.7B0%
Annual Yield % from dividends0.000.83-
Returns for 1 year15.6916.2397%
Returns for 3 years-15.78-25.4262%
Returns for 5 years15.7820.1978%
Returns for 10 years58.50N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NSA43.130.80
+1.89%
National Storage Affiliates Trust
CISS1.110.02
+1.83%
C3is
UTI19.610.07
+0.36%
Universal Technical Institute
TXT84.91-1.19
-1.38%
Textron
HRTX1.19-0.05
-4.03%
Heron Therapeutics